Complete remission of brain metastases from ovarian carcinoma with carboplatin

• Published in: European journal of obstetrics & gynecology and reproductive biology Vol. 78; no. 1; pp. 91 - 93
• Main Authors: Cormio, Gennaro, Gabriele, Antonio, Maneo, Andrea, Zanetta, Gerardo, Bonazzi, Cristina, Landoni, Fabio
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.05.1998; Elsevier
• Subjects: Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Brain metastasis; Brain Neoplasms - drug therapy; Brain Neoplasms - secondary; CA-125 Antigen - blood; Carboplatin; Carboplatin - administration & dosage; Carboplatin - therapeutic use; Chemotherapy; Cystadenoma, Serous - drug therapy; Cystadenoma, Serous - pathology; Cystadenoma, Serous - secondary; Fatal Outcome; Female; Humans; Medical sciences; Middle Aged; Ovarian carcinoma; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Pharmacology. Drug treatments; Remission Induction; Ovarian carcinoma; Carboplatin; Brain metastasis; Antineoplastic agent; Human; Nervous system diseases; Carcinoma; Malignant tumor; Metastasis; Female genital diseases; Cerebral disorder; Case study; Ovarian diseases; Ovary; Chemotherapy; Treatment; Central nervous system disease; Total; Female; Remission; Brain (vertebrata); Platinum II Complexes
• ISSN: 0301-2115; 1872-7654
• DOI: 10.1016/S0301-2115(98)00009-8

Central nervous system involvement by epithelial ovarian carcinoma is rare. We report the case of a 49 year old woman with stage IV serous carcinoma of the ovary who developed multiple cerebral and cerebellar metastases 7 months after achieving complete response to platin-based chemotherapy. Eight courses of carboplatin (400 mg/m 2) were administered and after the second cycle complete remission of the brain deposits occured. The treatment afforded rapid subjective and objective relief and was associated with a good quality of life. Abdominal recurrent disease was diagnosed 22 months after treatment for brain involvement. Paltin-based chemotherapy was reinstated, but the patient died from progressive adbominal disease without any sign of cerebral involvement and any neurological symptomatology. Carboplatin should be considered for the treatment of ovarian carcinoma metastatic to the brain.